Created at	Source	Raw Value	Validated value
Sept. 11, 2021, 4 a.m.	usa	Immunogenicity of MVC-COV1901;Incidence of Adverse Event within 28 days post the second study intervention (Safety of MVC-COV1901)	Immunogenicity of MVC-COV1901;Incidence of Adverse Event within 28 days post the second study intervention (Safety of MVC-COV1901)